These multi-functional DNA-based NGs were site-specifically functionalized with targeting ligands (anti-MUC1 aptamer) to target O-glycosylated protein Mucin 1 (MUC1) overexpressing human MCF-7 breast tumor cells with DOX resistance (MCF-7R), and provides controlled-release elements (GSH-responsive disulfide bridges) for the co-delivery of DOX chemodrugs and gene therapy drugs [111] (Figure 3). This evidence concerns the gene MUC1 and breast neoplasm.